Valuation : Immunic, Inc.

Market Cap 174M 150M 141M 129M 241M 16.44B 242M 1.67B 646M 8.43B 654M 640M 27.17B P/E 2026 *
-3.54x
P/E 2027 * -5.23x
Enterprise Value -106M -91.04M -85.65M -78.25M -146M -9.99B -147M -1.01B -393M -5.12B -397M -389M -16.51B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.03%
Yield 2026 *
-
Yield 2027 * -
1 day+2.74%
1 week-14.87%
Current month-17.03%
1 month-6.69%
3 months-9.15%
6 months+12.05%
Current year+145.64%
1 week 11.56
Extreme 11.56
16.1
1 month 11.56
Extreme 11.56
17.43
Current year 5.37
Extreme 5.372
17.43
1 year 5.06
Extreme 5.062
17.43
3 years 5.06
Extreme 5.062
21.1
5 years 5.06
Extreme 5.062
145
10 years 5.06
Extreme 5.062
289.9
Manager TitleAgeSince
Chief Executive Officer 48 01/06/2026
Director of Finance/CFO 58 17/04/2020
President 49 12/07/2024
Director TitleAgeSince
Director/Board Member 59 01/04/2019
Chairman 55 01/01/2019
Director/Board Member 64 19/11/2019
Date Insider Type Main position Quantity % Market Cap. Importance
06/08/26 Free

Director

50,740 0.3725%
05/07/26 Free

Director

25,370 0.1862%
05/07/26 Free

Director

25,370 0.1862%
Change 5-day change 1-year change 3-year change Capi.($)
+2.74%-14.87%+70.26%-20.06% 174M
-1.79%-3.82%+38.74%+91.90% 69.02B
-2.06%-1.52%+46.40%+86.87% 66.32B
-0.31%+6.54%-11.39%+378.92% 27.66B
+0.86%+1.65%+0.25%-14.95% 25.84B
-3.00%-2.61%+34.45%+11.39% 26.54B
-1.46%-0.09%+24.64%-18.36% 20.4B
-2.96%-16.03%+213.13%+375.00% 17.63B
-1.49%-6.69%-4.69%+539.74% 15.15B
-0.20%+8.37%+57.87%+164.98% 14.65B
Average -0.93%-2.77%+46.96%+159.54% 28.34B
Weighted average by Cap. -1.49%-0.47%+40.25%+138.78%

Financials

2026 *2027 *
Net sales - -
Net income -138M -119M -112M -102M -191M -13.05B -192M -1.32B -513M -6.7B -519M -508M -21.57B -152M -131M -123M -112M -210M -14.32B -210M -1.45B -563M -7.35B -570M -557M -23.67B
Net Debt -280M -241M -227M -207M -387M -26.43B -388M -2.68B -1.04B -13.56B -1.05B -1.03B -43.68B -404M -347M -327M -299M -559M -38.13B -560M -3.86B -1.5B -19.56B -1.52B -1.48B -63.02B
Logo Immunic, Inc.
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Employees
100
Date Price Change Volume
05/09/26 $13.11 +2.74% 419,462
03/09/26 $12.76 -10.39% 841,955
02/09/26 $14.24 -2.33% 225,157
01/09/26 $14.58 -7.72% 230,232
31/08/26 $15.80 +2.60% 124,872
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
12.76USD
Average target price
43.09USD
Spread / Average Target
+237.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMUX Stock